When was Amicas founded?
Amicas was founded in 1995.
Where is Amicas's headquarters?
Amicas's headquarters is located at 1210 Washington Street, Newton.
What is Amicas's latest funding round?
Amicas's latest funding round is Acq - P2P.
How much did Amicas raise?
Amicas raised a total of $30.67M.
Who are the investors of Amicas?
Investors of Amicas include Merge Healthcare, VitalWorks, One Equity Partners, Beringea, Radius Ventures and 6 more.
Who are Amicas's competitors?
Competitors of Amicas include Abaxis, Applied Spectral Imaging, Fenwal, Micronics Microfluidics, Inoveon and 11 more.
You May Also Like
OraMetrix is a provider of 3-D technology solutions improving the quality and efficiency of orthodontic care. Its proprietary technology, the suresmile system, allows the use of precision digital tools throughout all phases of the orthodontic treatment process – diagnosis, treatment planning and monitoring, and archwire customization.
Forth Photonics is a medical device company that designs, develops, manufactures and markets imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. Forth Photonics aims to help medical practitioners to improve patient care by incorporating advanced biophotonics and optical molecular imaging technologies to assist in early detection, diagnosis and monitoring.
Cardiophotonics develops non invasive blood monitors used to detect cardiac arrhythmia and dehydration
Verax Biomedical is the producer of the Platelet PGD Test, a test for bacterial contamination in platelets granted a Safety Measure claim by the FDA. The test can be used to extend the dating of apheresis platelets in plasma, the most common platelet type transfused in the U.S., from 5 to 7 days. This dating extension offers the opportunity for significant cost savings to the blood banking community while preserving a critical life giving resource.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Imorphics is a spin-out from the Division of Imaging Science and Biomedical Engineering in the Faculty of Medicine and is based on more than 20 year's research led by Professor Chris Taylor. The company sells 3D medical image analysis software which is being used to improve the speed and accuracy of measurements taken in drug trials. MTF introduced Chairman Mike Bowes to the company. Mike Bowes was previously CEO of Kestra, an imaging start-up backed by 3i which was sold in 1999.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.